Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience

Angiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous non-small cell lung cancer patients. This review focuses first on the da...

Full description

Bibliographic Details
Main Authors:	Laurent Greillier, Pascale Tomasini, Fabrice Barlesi
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-10-01
Series:	Therapeutic Advances in Respiratory Disease
Online Access:	https://doi.org/10.1177/1753465816652083

id	doaj-7fa21e5a8d3941548d4fdd09575d3d28
record_format	Article
spelling	doaj-7fa21e5a8d3941548d4fdd09575d3d282020-11-25T03:18:05ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46581753-46662016-10-011010.1177/1753465816652083Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experienceLaurent GreillierPascale TomasiniFabrice BarlesiAngiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous non-small cell lung cancer patients. This review focuses first on the data from clinical trials available to date regarding efficacy and safety of chemotherapy plus bevacizumab. This review then highlights the current remaining questions related to the use of this drug in daily practice and how the patients might be clinically and radiologically selected. Finally, this review explores the future directions for bevacizumab development in nonsquamous non-small cell lung cancer and for a biological selection of patients with research on predictive biomarkers.https://doi.org/10.1177/1753465816652083
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Laurent Greillier Pascale Tomasini Fabrice Barlesi
spellingShingle	Laurent Greillier Pascale Tomasini Fabrice Barlesi Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience Therapeutic Advances in Respiratory Disease
author_facet	Laurent Greillier Pascale Tomasini Fabrice Barlesi
author_sort	Laurent Greillier
title	Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
title_short	Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
title_full	Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
title_fullStr	Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
title_full_unstemmed	Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
title_sort	bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
publisher	SAGE Publishing
series	Therapeutic Advances in Respiratory Disease
issn	1753-4658 1753-4666
publishDate	2016-10-01
description	Angiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage IV nonsquamous non-small cell lung cancer patients. This review focuses first on the data from clinical trials available to date regarding efficacy and safety of chemotherapy plus bevacizumab. This review then highlights the current remaining questions related to the use of this drug in daily practice and how the patients might be clinically and radiologically selected. Finally, this review explores the future directions for bevacizumab development in nonsquamous non-small cell lung cancer and for a biological selection of patients with research on predictive biomarkers.
url	https://doi.org/10.1177/1753465816652083
work_keys_str_mv	AT laurentgreillier bevacizumabinthetreatmentofnonsquamousnonsmallcelllungcancerclinicaltrialevidenceandexperience AT pascaletomasini bevacizumabinthetreatmentofnonsquamousnonsmallcelllungcancerclinicaltrialevidenceandexperience AT fabricebarlesi bevacizumabinthetreatmentofnonsquamousnonsmallcelllungcancerclinicaltrialevidenceandexperience
_version_	1724628872631156736

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience

Similar Items